File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients

TitleNanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients
Authors
KeywordsCD20
ROR1
Rituximab
Non-Hodgkin's lymphoma
Cancer cell
Atomic force microscopy
Issue Date2013
Citation
Experimental Cell Research, 2013, v. 319, n. 18, p. 2812-2821 How to Cite?
AbstractCD20, a membrane protein highly expressed on most B-cell lymphomas, is an effective target demonstrated in clinical practice for treating B-cell non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. In this work, we applied atomic force microscopy (AFM) to map the nanoscale distribution of CD20 molecules on the surface of cancer cells from clinical B-cell NHL patients under the assistance of ROR1 fluorescence recognition (ROR1 is a specific cell surface marker exclusively expressed on cancer cells). First, the ROR1 fluorescence labeling experiments showed that ROR1 was expressed on cancer cells from B-cell lymphoma patients, but not on normal cells from healthy volunteers. Next, under the guidance of ROR1 fluorescence, the rituximab-conjugated AFM tips were moved to cancer cells to image the cellular morphologies and detect the CD20-rituximab interactions on the cell surfaces. The distribution maps of CD20 on cancer cells were constructed by obtaining arrays of (16×16) force curves in local areas (500×500nm2) on the cell surfaces. The experimental results provide a new approach to directly investigate the nanoscale distribution of target protein on single clinical cancer cells. © 2013 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/213362
ISSN
2023 Impact Factor: 3.3
2023 SCImago Journal Rankings: 0.947
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, Mi-
dc.contributor.authorXiao, Xiubin-
dc.contributor.authorLiu, Lianqing-
dc.contributor.authorXi, Ning-
dc.contributor.authorWang, Yuechao-
dc.contributor.authorDong, Zaili-
dc.contributor.authorZhang, Weijing-
dc.date.accessioned2015-07-28T04:07:01Z-
dc.date.available2015-07-28T04:07:01Z-
dc.date.issued2013-
dc.identifier.citationExperimental Cell Research, 2013, v. 319, n. 18, p. 2812-2821-
dc.identifier.issn0014-4827-
dc.identifier.urihttp://hdl.handle.net/10722/213362-
dc.description.abstractCD20, a membrane protein highly expressed on most B-cell lymphomas, is an effective target demonstrated in clinical practice for treating B-cell non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. In this work, we applied atomic force microscopy (AFM) to map the nanoscale distribution of CD20 molecules on the surface of cancer cells from clinical B-cell NHL patients under the assistance of ROR1 fluorescence recognition (ROR1 is a specific cell surface marker exclusively expressed on cancer cells). First, the ROR1 fluorescence labeling experiments showed that ROR1 was expressed on cancer cells from B-cell lymphoma patients, but not on normal cells from healthy volunteers. Next, under the guidance of ROR1 fluorescence, the rituximab-conjugated AFM tips were moved to cancer cells to image the cellular morphologies and detect the CD20-rituximab interactions on the cell surfaces. The distribution maps of CD20 on cancer cells were constructed by obtaining arrays of (16×16) force curves in local areas (500×500nm2) on the cell surfaces. The experimental results provide a new approach to directly investigate the nanoscale distribution of target protein on single clinical cancer cells. © 2013 Elsevier Inc.-
dc.languageeng-
dc.relation.ispartofExperimental Cell Research-
dc.subjectCD20-
dc.subjectROR1-
dc.subjectRituximab-
dc.subjectNon-Hodgkin's lymphoma-
dc.subjectCancer cell-
dc.subjectAtomic force microscopy-
dc.titleNanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.yexcr.2013.07.020-
dc.identifier.pmid23896027-
dc.identifier.scopuseid_2-s2.0-84886255045-
dc.identifier.volume319-
dc.identifier.issue18-
dc.identifier.spage2812-
dc.identifier.epage2821-
dc.identifier.eissn1090-2422-
dc.identifier.isiWOS:000326432700006-
dc.identifier.issnl0014-4827-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats